Exscientia, a company focusing on AI-powered drug discovery, has raised $225M in a Series D led by SoftBank Group. It also secured a $300M convertible note from SoftBank.

360 Mobile Vision - 360mobilevision.com North & South Carolina Security products and Systems Installations for Commercial and Residential - $55 Hourly Rate. ACCESS CONTROL, INTRUSION ALARM, ACCESS CONTROLLED GATES, INTERCOMS AND CCTV INSTALL OR REPAIR 360 Mobile Vision - 360mobilevision.com is committed to excellence in every aspect of our business. We uphold a standard of integrity bound by fairness, honesty and personal responsibility. Our distinction is the quality of service we bring to our customers. Accurate knowledge of our trade combined with ability is what makes us true professionals. Above all, we are watchful of our customers interests, and make their concerns the basis of our business.

How’s the company performing?

  • Oxford-based Exscientia uses AI to precision engineer new drugs. The company has pushed 2 drugs into clinical trials to date and has another 20 active programs in the pipeline.
  • In January 2020, Exscientia and partner Dainippon Pharma announced that their first AI-designed drug candidate, a treatment for obsessive-compulsive disorder, had advanced into clinical trials. The process took just a year, compared to the average timeline of 4.5 years.
  • Exscientia currently has over 100 employees across 20 countries and recently expanded into the US, in Miami and Boston.
  • It has raised more than $672M to date. In March 2021, Exscientia raised a $40M Series C-II with participation from BlackRock.

Want the full post? Become a CB Insights customer.

If you’re already a customer, log in here.

The post Softbank-Backed Exscientia Raises $225M To Enhance Its Autonomous Drug Design Platform appeared first on CB Insights Research.

By admin